Item 8.01. Other Events.

On June 9, 2009, Keryx Biopharmaceuticals, Inc. (the "Company") issued a press release announcing that on June 5, 2009, it received a letter from the Nasdaq Stock Market ("Nasdaq") granting the Company an extension through August 31, 2009, to regain compliance with Nasdaq Listing Rule 5550(b). Nasdaq Listing Rule 5550(b) requires the Company to have a minimum of $2,500,000 in stockholders' equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years for continued listing on The Nasdaq Capital Market. The press release announcing the extension is attached as Exhibit 99.1 to this report, and is incorporated herein by reference.

The Company expects to be able to comply with Nasdaq Listing Rule 5550(b) for continued listing on The Nasdaq Capital Market by August 31, 2009; however, there can be no assurance that the Company will be able to do so. Failure to comply with the conditions for listing could result in the delisting of the Company's common stock from The Nasdaq Capital Market.

Cautionary Statement

Some of the statements included herein may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth herein speak only as of the date of this Form 8-K. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

---